AKESO INC. O.N.
Research AKESO INC. O.N. (4RY) on Bullrun: market cap EUR 9.72B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4RY
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 9.72B
- Financial periodFY2025
- RevenueCNY 3.06B
- Revenue growth43.9%
- Net income-CNY 1.11B
- Free cash flow-CNY 1.73B
- Gross margin78.7%
Valuation Snapshot
latest market cap is EUR 9.72B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.06B | -CNY 1.11B | -CNY 1.73B | 78.7% | -1.23 | CNY 8.78B | CNY 4.56B | CNY 9.05B |
| FY2024 | CNY 2.12B | -CNY 514.52M | -CNY 1.12B | 86.4% | -0.6 | CNY 6.89B | CNY 3.95B | CNY 6.81B |
| FY2023 | CNY 4.53B | CNY 2.03B | CNY 1.59B | 97.1% | 2.42 | CNY 4.03B | CNY 2.99B | CNY 4.69B |
| FY2022 | CNY 837.66M | -CNY 1.17B | -CNY 2.04B | 88.8% | -1.42 | CNY 2.09B | CNY 1.88B | CNY 2.64B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 9.72B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AKESO INC. O.N.'s market cap?
AKESO INC. O.N.'s market capitalization is EUR 9.72B.
What does AKESO INC. O.N. do?
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.